We are live on ! Find out more
MDNA

Medicenna Therapeutics Corp. Common Shares

Delisted

MDNA was delisted on the 1st of November, 2023.

27 hedge funds and large institutions have $4.43M invested in Medicenna Therapeutics Corp. Common Shares in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

4% less funds holding

Funds holding: 2827 (-1)

45% less capital invested

Capital invested by funds: $8.11M → $4.43M (-$3.67M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
27
Holders Change
-1
Holders Change %
-3.57%
% of All Funds
0.43%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
5
Increased
7
Reduced
3
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$824
ASN
27
Advisory Services Network
Georgia
$342 +$456 +747 New
GPCM
28
Granite Point Capital Management
Massachusetts
-$270K -325,000 Closed
MS
29
Maven Securities
Jersey
-$124K -150,000 Closed
Toronto Dominion Bank
30
Toronto Dominion Bank
Ontario, Canada
-$2K -2,100 Closed
Bank of America
31
Bank of America
North Carolina
-$1K -1,500 Closed

MDNA Hedge Fund Activity: Q4 2022 in Review

27 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Medicenna Therapeutics Corp. Common Shares (MDNA) for Q4 2022, worth a combined $4.43M — down 45% from $8.11M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new MDNA positions and 4 closed out — a net gain of 1 holder — while 7 added to existing stakes and 3 trimmed.

The largest buyer was AIGH Capital Management, adding an estimated $303K. The largest seller was Granite Point Capital Management, exiting entirely with an estimated $270K sold.

  • 27 institutional investors held Medicenna Therapeutics Corp. Common Shares (MDNA) as of Q4 2022, down from 28 in Q3 2022.
  • Funds reported $4.43M of Medicenna Therapeutics Corp. Common Shares stock for Q4 2022, down 45% quarter-over-quarter.
  • 5 funds opened new Medicenna Therapeutics Corp. Common Shares positions in Q4 2022 and 4 closed out, a net change of +1 holder.
  • The largest Medicenna Therapeutics Corp. Common Shares buyer in Q4 2022 was AIGH Capital Management, an estimated $303K added.
  • The largest Medicenna Therapeutics Corp. Common Shares seller in Q4 2022 was Granite Point Capital Management, an estimated $270K sold.

Based on aggregated 13F filings for Q4 2022.